Proteomic Solutions
A content and news platform that aggregates technical summaries, study results and industry developments in proteomics and related molecular-biology fields. Coverage emphasizes plasma and biofluid proteomics, biomarker discovery and validation, analytical workflows (mass spectrometry and multiplex assays), extracellular vesicle methods, computational proteomics and translational applications for diagnostics, large-cohort studies and precision medicine.
Industries
Nr. of Employees
small (1-50)
Proteomic Solutions
Saint-marcel, Haute-Normandie, France, Europe
Expertise Areas
- Plasma and biofluid proteomics with preanalytical standardization
- Biomarker discovery and clinical assay validation for non-invasive diagnostics
- Extracellular vesicle isolation, characterization and reference materials
- Mass spectrometry-based proteomics (DIA) and large-cohort scale-up
Key Technologies
- Data-independent acquisition mass spectrometry (DIA-MS)
- High-resolution mass spectrometry
- High-capacity mass spectrometry infrastructure for large-cohort studies
- Automated high-throughput proteomic screening platforms
News & Updates
Summary of how preanalytical variables (phlebotomy, anticoagulant choice, centrifugation, storage) affect plasma proteomics reproducibility and recommendations for standardization.
Coverage of high-purity lyophilized exosome reference materials and EV isolation and characterization methods (TFF, SEC) to improve reproducibility in extracellular vesicle research.
Report on an expanded partnership to validate a blood-based proteomic test for endometriosis, noting addition of clinical samples and plans for non-invasive diagnostic deployment.
Industry coverage of an acquisition integrating high-plex proteomic assay capability into broader sequencing and multi-omic platforms and its anticipated impact on research tools.
Overview of advances in immunoproteomics and methods for identifying tumor-associated antigens using immunoassays, expression-library screening and mass spectrometry.
Summary of a pan-disease blood proteome map describing ~5,400 proteins across multiple diseases and healthy controls, and AI analysis to define disease-specific proteomic signatures.
Summary of how preanalytical variables (phlebotomy, anticoagulant choice, centrifugation, storage) affect plasma proteomics reproducibility and recommendations for standardization.
Coverage of high-purity lyophilized exosome reference materials and EV isolation and characterization methods (TFF, SEC) to improve reproducibility in extracellular vesicle research.
Report on an expanded partnership to validate a blood-based proteomic test for endometriosis, noting addition of clinical samples and plans for non-invasive diagnostic deployment.
Industry coverage of an acquisition integrating high-plex proteomic assay capability into broader sequencing and multi-omic platforms and its anticipated impact on research tools.
Overview of advances in immunoproteomics and methods for identifying tumor-associated antigens using immunoassays, expression-library screening and mass spectrometry.
Summary of a pan-disease blood proteome map describing ~5,400 proteins across multiple diseases and healthy controls, and AI analysis to define disease-specific proteomic signatures.